FIA
THE FRAUD

"Significant progress" with a large Canadian pharmacy retailer that requested point-of-purchase displays and would put the product in stores, first shipment expected fall 2016. E-commerce channels showed "brisk sales traffic." — Press release, May 18, 2016

No shipment, no order fulfillment, no material revenue — ever — in the 2016 and 2017 audited financial statements. Intercept CS then vanished from disclosure while lingering in boilerplate "About" sections for years. A third party later publicly claimed to be sitting on ~$600,000 of Intercept CS inventory. The financials never showed it, sold it, or wrote it down.

"A leader and early mover in this space" — working prototype in 4–6 weeks, in-vitro testing against Zika and West Nile by end of Q1 2017 at a "world renowned scientific research lab." — Press release, Jan 24, 2017

Then: results "indicate effectiveness in inhibiting Zika virus" at Techna Institute/UHN — Press release, Jan 8, 2018, and by 2019 the company was in "final stages of in vitro testing" with results expected "in the near future." — Press release, Mar 28, 2019

In three years of announcements about a global virus panic, not one final test result was ever disclosed. No regulatory clearance. No commercialization. No revenue line. The "near future" arrived, and TherOZap was never meaningfully mentioned again. It, too, survived for years in boilerplate as if it were a real asset.

"Exceptional" Brazilian clinical results exceeding FDA minimums. EU-CE approval plus a conditional order for 100,000 units. Detection of the Delta variant. A manufacturing partner with capacity of 500,000+ units per month. — Press releases: EU-CE approval + 100,000-unit order (Apr 19) · 500,000+/month manufacturing partner (May 21) · “exceptional” Brazilian results (Jun 17) · Delta variant detection (Jul 8)

"On track to be the first COVID-19 rapid antigen saliva test to receive FDA Emergency Use Authorization" — and in January 2022, the U.S. clinical study was "still underway" with "current results very promising." — Press release, Jul 22, 2021 · Press release, Jan 20, 2022

Negligible or zero COVID-test revenue — in every audited financial statement, 2021 through 2025. No inventory build, no order fulfillment, no accounts receivable at even a fraction of the announced scale. No EUA was ever received — and none was ever announced as denied, delayed, or abandoned. The "very promising" U.S. study's final results have never been disclosed anywhere, by anyone, in any form. At the height of a global pandemic with every claimed advantage, the audited statements show they sold next to nothing.

An "exclusive U.S. distributor" deal with a $10 Million annual minimum purchase commitment, an initial 5,000-unit order, and a "$1 Billion market opportunity." — Press release, Jun 28, 2021

First 2,500 units shipped, units "sold to customers in the US," partial payment received. Then in 2023: "Secures Medicare and Medicaid Reimbursement" with nine temporary CPT®/HCPCS codes paying $725–$1,050 per pair. Then in 2024: a permanent HCPCS code with a $1,199 "buyout", "110+ units deployed" with "100% reimbursement success," and a new $6M DME Authority commitment for 2025. — “nine temporary codes” (Apr 14, 2023) · permanent code + $1,199 “buyout” (Aug 19, 2024) · “100% reimbursement success” (Dec 5, 2024) · new $6M DME LOI (Dec 18, 2024)

Every CMS HCPCS coding-cycle document for 2022–2025 — the complete public record, more than 1,000 pages — contains zero mention of Therma Bright, Venowave, or any temporary code. The "temporary codes" never existed. The market traded for over a year on that fiction. The permanent code the device eventually received (E0683) is rental-only, capped around $819.55 over 13 months — nothing like $725–$1,199 per unit. And the audited financials show negligible or zero device revenue in every single year the "$10 million annual minimum" was supposedly running.

A "game-changing" clot retriever — "the first and only" of its kind — with 80%+ animal trial success, up to $2.5M invested for up to 25% ownership. — Press release, Jan 19, 2023

A GLP study removing "100% of the clot in 100% of the cases," called a "life saving ischemic stroke treatment technology." A new manufacturing facility. Then a "Major Milestone": a third completed human trial with "promising initial results." — GLP study, “100% of the clot” (Jun 7, 2023) · 3rd human trial “milestone” (Aug 27, 2024)

The fiscal 2025 audited financial statements record full impairment of both the Inretio and InStatin investments — written down to zero. Total loss. And no press release, material change report, or correction was ever issued disclosing it. The company kept publishing upbeat "milestone" and "exciting progress" language about assets its own auditors had already valued at nothing.

An "AI-powered" smartphone cough analyzer. The FDA 513(g) request had been "prepared" — Press release, Nov 29, 2023, the effort "continued", with potential CMS reimbursement codes and a possible chronic-cough drug trial partnership. — Press release, Aug 16, 2024

No submission status. No FDA response. No classification. No partnership contract. No revenue. Zero corresponding activity in the audited financials. When the well of pandemic buzzwords ran dry, "AI" served exactly the same function Zika had in 2017: a story to raise money against, with nothing behind it and no obligation ever taken to tell investors how it ended.

In 2018: “targeting entry into the Canadian Medical and Recreational market in 2018 as a high quality, large-scale cannabis producer.” — Newsfile release, May 2018

Then: the Health Canada processing licence arrives (April 2021) for a self-described “leading consumer packaged goods company” building cannabis-infused edibles; retail stores open through Budd Hutt; Pawsperity™ dog treats launch at Petvalu; the company “prepares for edibles manufacturing.” — Licence, Apr 2021 · Petvalu launch, Apr 2022 · “Prepares,” Oct 2021

The entire announced commercial footprint, eight years in: a purchase order to produce two cannabis-infused products (June 2022), and a release celebrating the shipment of three cannabis-infused sauces (October 2022). Then the real business begins: promissory notes, revolving credit lines, warrant-incentive programs, a strategic review, and the same $1,000,000 private placement announced and re-extended again and again.

By April 2024 the company exits retail cannabis. In November 2024 it clears $2.3M of debt with 78,083,779 shares at $0.03. In 2025 the cannabis assets are spun out and the stock is consolidated — twice, in the same month.

A binding LOI to buy up to 20% of ArkenYield, a “pioneering digital asset yield platform,” for $575,000 — and a refocus from “cannabis issuer” to “investment issuer.” — Newsfile release, Jul 15, 2025

Then the proposed name change to “Stable Capital Holdings Inc.” — Sep 30, 2025, a partnership “to Manage up to $500M for Institutional Depositors” with “capacity for up to $500 million in stablecoin commitments” — Oct 15, 2025, an LOI with a “major digital asset infrastructure provider,” its own stablecoin rating standard, a “Circle Alliance Partnership,” and — October 21, 2026 — a “$50 Million Yield Infrastructure Arrangement.” — Dec 2025 · Feb 2026 · Apr 2026 · Oct 21, 2026

Read the release, not the headline. The “$500M” is capacity, not assets — announced by a company that, per its own later filing, never actually acquired the stake: the August 2026 update states the original $575,000 / 20% agreement was “cancelled and terminated,” that “no closing occurred,” and that no shares of ArkenYield, shares of City View, debenture or warrants were ever issued, transferred or delivered. The same update put the platform’s “tangible, operating use case” — a live vault — at just over US$655,000, and revised the structure so City View’s side ends up with 10% of the new entity (the founder and his advisors: 90%) while City View issues the founder 2.5 million more shares and warrants. If under US$400,000 is funded by December 7, 2026, the entire transaction terminates. — City View release, Aug 19, 2026

The October 21, 2026 “$50 million” is a non-binding MOU whose own text concedes the figure “does not constitute committed capital, guaranteed assets under management, or a confirmed deployment amount.” Meanwhile, in May 2026, City View settled $897,106.66 of debt with 12,815,807 shares — with Rob Fia personally receiving 4,953,828 shares for $346,768 the company owed him. — Oct 21, 2026 MOU · May 1, 2026 debt settlement